Antibiotics: New Breakthroughs Are Positive Developments, Yet Humanity Are Falling Behind In the Bigger Race

During a time as head of the World Health Organization, a former leader famously stated that all of the “simple” antibiotics had long since been discovered. The point was that in tackling the pressing danger of drug-resistant bacterial infections, we would struggle to discover new medicines – or conserve the current arsenal – without developing novel approaches of operating. This assessment proved correct.

A Slow and Challenging Pipeline

Since the late 2010s, just 16 antimicrobial agents have gained broad regulatory approval – primarily close relatives of medicines currently available and thus unlikely to overcome bacterial resistance for long. The development of novel compounds is a slow and unprofitable endeavor, given that curative treatments are less lucrative as those treating longer-term ailments. The overall prospect continues to be grim.

A Spark of Hope and a New Model

However, the recent announcement of two new FDA-approved antibiotics for gonorrhea is good news and, crucially, confirms a innovative method of incentivising research. A particular of the recently approved medications, Zoliflodacin, is the product of a unique type of collaboration between a global health organization and a drug firm. The non-profit supplied financial support and organised clinical trials to offset expenses and clear regulatory hurdles. This type of assistance in advance helps direct the sector towards areas of most pressing public health necessity.

This approach and a separate praised revenue guarantee scheme – launched to ensure income to firms investing in specific antimicrobials – constitute the strongest chance of sustaining a dripfeed of novel treatments from the current framework.

The Unavoidable Challenge of Resistance

But even hurrying the production of compounds currently in development isn't enough. Zoliflodacin is sometimes categorized as a novel type of antibiotic, indicating it attacks a component of the infectious bacteria that existing treatments does, theoretically compelling the bacterium to begin anew in evolving a countermeasure to it. Scientists and physicians are relieved to have a new option for gonorrhoea – which has strains resistant to all existing treatments – but caution that eventual drug resistance to it is inevitable.

As has grown customary with new antibiotics, there is therefore an argument about whether it should be stockpiled, rationed to extremely drug-resistant cases only – limiting its use to settings where high‑end lab testing is accessible. This sort of prudent strategy should be the worldwide norm, but often can't be implemented readily in many regions.

A Diminishing Pipeline of Discovery

More broadly, it is hard to see where the flow of additional novel antimicrobials we require could possibly come from. The aforementioned statement nodded to the fact that surveying the living world for biological compounds – as with the first antibiotic – has had diminishing returns. Use of AI has been proposed to speed up the discovery process, although a highly-touted initial discovery found in 2020 hasn't yet progressed past preclinical studies. Fully lab-created compounds, that are largely or entirely synthesized, are constantly in development, but often run up against the fundamental rules of molecular science – just because we imagine a molecule doesn't mean we can create it easily.

Moving Quickly to Stand Still

The dominant expert assessment is that when it comes to antimicrobials, we must move with great speed truly just to remain in the same place. Prudent, internationally coordinated use is the sole method to preserve our advantage. Sadly, the magnitude of future breakthroughs is likely to seem meager in contrast to the curative bonanza of the 20th century.